Programming of cells for tolerogenic therapies
AssigneesForsyth Dental Infirmary for Children, President and Fellows of Harvard College
InventorsRoger Warren Sands, Eduardo Alexandre Barros e Silva, Toshihisa Kawai, David J. Mooney
Life of this patent
Estimating the term…
Abstract
Biomaterial systems, e.g., gel scaffolds, are used in vivo to recruit immune cells and promote their activation towards a non-inflammatory phenotype, thereby leading suppression of inflammation. The compositions and methods are useful to reduce the severity of autoimmunity, chronic inflammation, allergy, and periodontal disease.
Claims23
-23. (canceled)
A method of reducing the severity of an autoimmune disorder, comprising identifying a subject suffering from an autoimmune disorder and administering to said subject a scaffold composition comprising an antigen, a recruitment composition, and a tolerogen,
- wherein said antigen is derived from a cell to which a pathologic autoimmune response associated with said disorder is directed;
- wherein said tolerogen induces immune tolerance or a reduction in an immune response;
- and
- wherein said tolerogen comprises dexamethasone, vitamin D, retinoic acid, rapamycin, aspirin, transforming growth factor beta, interleukin-10, or vasoactive intestinal peptide.
Dependencies are inferred from the claim text.